LuPIN trial data will be presented by A/Professor Louise Emmett at the ASCO GU Conference in San Francisco 13-15 Feb 2020, according to the NOX website
GK said at the last AGM that the LuPIN trial was great value for money, costing just $5,000 per patient; and that data so far for LuPSMA + NOX66 was clearly superior to LuPSMA alone. I expect to see that superiority reinforced in the February presentation.
LuPIN trial data will be presented by A/Professor Louise Emmett...
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.04M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 72463 | 6.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 8810 | 1 |
View Market Depth
| Last trade - 10.16am 29/07/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
Day chart unavailable